Bicycle Therapeutics PLC
NASDAQ:BCYC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.46
27.51
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BCYC stock under the Base Case scenario is 11.86 USD. Compared to the current market price of 23.42 USD, Bicycle Therapeutics PLC is Overvalued by 49%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Bicycle Therapeutics PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BCYC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Bicycle Therapeutics PLC
Balance Sheet Decomposition
Bicycle Therapeutics PLC
Current Assets | 966.2m |
Cash & Short-Term Investments | 890.9m |
Receivables | 58m |
Other Current Assets | 17.4m |
Non-Current Assets | 30.6m |
PP&E | 20.6m |
Other Non-Current Assets | 9.9m |
Current Liabilities | 56.4m |
Accounts Payable | 5.7m |
Accrued Liabilities | 38.7m |
Other Current Liabilities | 12m |
Non-Current Liabilities | 109.3m |
Other Non-Current Liabilities | 109.3m |
Earnings Waterfall
Bicycle Therapeutics PLC
Revenue
|
36.9m
USD
|
Operating Expenses
|
-233.4m
USD
|
Operating Income
|
-196.5m
USD
|
Other Expenses
|
30.2m
USD
|
Net Income
|
-166.3m
USD
|
Free Cash Flow Analysis
Bicycle Therapeutics PLC
USD | |
Free Cash Flow | USD |
BCYC Profitability Score
Profitability Due Diligence
Bicycle Therapeutics PLC's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Bicycle Therapeutics PLC's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
BCYC Solvency Score
Solvency Due Diligence
Bicycle Therapeutics PLC's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Bicycle Therapeutics PLC's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCYC Price Targets Summary
Bicycle Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for BCYC is 40.06 USD with a low forecast of 28.28 USD and a high forecast of 58.8 USD.
Dividends
Current shareholder yield for BCYC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BCYC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 119 full-time employees. The company went IPO on 2019-05-23. The firm is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.
Contact
IPO
Employees
Officers
The intrinsic value of one BCYC stock under the Base Case scenario is 11.86 USD.
Compared to the current market price of 23.42 USD, Bicycle Therapeutics PLC is Overvalued by 49%.